Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

Recent Advances in Cancer Treatment — Summary

Recent Advances in Cancer Treatment — Summary

Outcomes for people diagnosed with cancer have changed over the past 50 years. While 5-year survival rates for patients diagnosed in the 1970s were around 30-40%, they reached 70% by 2010; today, the figures are even more encouraging.

What is the 5-year survival rate? This rate indicates the percentage of patients who live for at least 5 years after a cancer diagnosis. In cancer, living for 5 years or longer is equivalent to completely treating the disease. 

There are 3 main reasons for improving cancer outcomes:

  1. Public health measures (such as smoking cessation education),
  2. Improved healthcare services (such as screening methods for early detection ), and
  3. New medications and their combinations.

These advances have transformed certain diagnoses once considered terminal (end-stage) into chronic diseases. For example, most patients now diagnosed with multiple myeloma or prostate cancer have a higher rate of death from conditions other than cancer.

However, much remains to be done. For pancreatic cancer and glioblastoma (GBM, a brain tumor), 5-year survival remains below 50%.

The greatest advance in oncology over the past 10 years has undoubtedly been immunotherapies. Every year, 2 million people are diagnosed with lung cancer. Before immunotherapy, advanced non-small cell lung cancer had a 5-year overall survival rate of around 10%. With immunotherapy, this has now risen to 25%; in other words, 1 in every 4 patients with advanced lung cancer now lives for 5 years or longer. This progress was achieved in just 5 years.

As important an advance as immunotherapy are the fruits of the Human Genome Project, namely targeted cancer drugs. Nearly 50 targeted cancer drugs developed against genetic targets are now used in cancer treatment.

Innovation in oncology has accelerated

After the first targeted drug for the HER2 breast cancer subtype, Herceptin, was approved in 1999, it took 8 years for a second HER2-directed drug to be approved. In contrast, the first drug to enter the market in 2013 and change ovarian cancer treatment, the PARP inhibitor, was followed by the next in less than 2 years. Globally, the next wave of innovation for patients is advancing at an increasingly rapid pace.

Both early diagnosis and molecular therapies through better imaging

The molecular imaging method PET-CT has become the standard approach for cancer diagnosis and assessment of treatment response. But it has not stopped there: in prostate cancer and neuroendocrine tumors, different PET approaches can be used for both imaging and treatment. For example, actinium therapy.

Much more precise oncology through genetic testing

Cancer is a group of diseases caused by the accumulation of damage in genes (see our article what is cancer ). Genes involved in cancer development are called “cancer genes”. Genetic damage associated with cancer mostly arises during life from environmental factors or aging; less commonly, it is inherited from parents. Detecting both changes that arise during life and those inherited from parents in cancer genes through genetic testing is a critical step in predicting the suitability of targeted drugs.

- Related topic: Familial, Hereditary, and Sporadic: Frequently Confused Concepts in Cancer 

Recent studies have highlighted the growing importance of inherited mutations in cancer; we now know that inherited mutations cause one in every 8 cancers. Identifying patients with inherited mutations not only guides treatment but also provides valuable information about their families’ risk and how they should be monitored.

Cancer treatment and screening should not be interrupted during COVID-19

According to a study whose results were announced in October, because of COVID-19, a 1-month delay in cancer treatment was associated with a 6-13% increase in deaths. Similarly, cancer screening for early detection has been disrupted worldwide. Both individuals and healthcare providers have responsibilities here. People with suspected cancer should not postpone seeking medical care out of fear of the coronavirus pandemic.

Conclusion

In conclusion, advances in oncology are improving outcomes for this challenging disease a little more every day. Precision medicine and new methods, including immunotherapies, are being continuously tested to extend patients’ lives and improve their quality of life.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

Recent Advances in Cancer Treatment — Summary

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy